On July 20, 2023, the United Kingdom issued the Cosmetic Products (Restriction of Chemical Substances) Regulations 2023 (No. 836 of 2023), to revise the requirements for the use of Methyl-N-methylanthranilate (CAS No. 85-91-6), HAA, and HAA (nano) (CAS No. 919803-06-8). This regulation applies to England, Wales, and Scotland.
Amendment to Annex 3 (comes into force on July 6, 2024).
Chemical Name/INN | Name of Common Ingredients Glossory | CAS number | EC number | Product type, Body parts | Maximum concentration in ready for use preparation | Other |
Methyl-N-methylanthranilate
|
| 85-91-6 | 201-642-6 | (a) Leave-on products (b) Rinse-off products | 0.1% 0.2% | For leave on products only: Not to be used in sunscreen products and products marketed for exposure to natural or artificial UV light. For leave-on and rinse-off products: Do not use with nitrosating agents; Maximum nitrosamine content: 50μg/kg; Keep in nitrite-free containers.” |
A cosmetic product that is placed on the market prior to July 6, 2024, can continue to be made available on the market until July 6, 2026.
Amendment to Annex 6 (comes into force on August 10, 2024).
Chemical Name/INN | Name of Common Ingredients Glossary | CAS number | EC number | Product type, Body parts | Maximum concentration in ready-for-use preparation | Other |
1,1’-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone | Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine
| 919803-06-8 | 485-100-6 |
| 10% | In case of combined use of Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine and Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (nano), the sum shall not exceed 10%. |
1,1’-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone | Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (nano)
| 919803-06-8 | 485-100-6 |
| 10% | Only nanomaterials having the following characteristics are allowed: - Purity ≥ 97%, - Median particle size D50 (50% of the number below this diameter): ≥ 50nm of number size distribution. Not to be used in applications that may lead to exposure of the end user’s lungs by inhalation. In case of combined use of Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine and Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (nano), the sum shall not exceed 10%. ” |
If you need any assistance or have any questions, please contact us at service@cirs-group.com.
